Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label Trial of CPI-613 (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

X
Trial Profile

A Phase I/II Open-Label Trial of CPI-613 (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Devimistat (Primary) ; Hydroxychloroquine (Primary)
  • Indications Clear cell sarcoma; Ewing's sarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms APOLLO 613
  • Sponsors Cornerstone Pharmaceuticals Inc
  • Most Recent Events

    • 22 May 2023 Status changed from recruiting to completed.
    • 10 Nov 2022 Planned number of patients changed from 65 to 59.
    • 07 Jun 2022 Planned number of patients changed from 47 to 65, as per Trial design, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top